Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults

NCT05210413 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Refractory or Recurrent Solid Tumor

Interventions

DRUG: Spartalizumab in Pediatric cohort
DRUG: Low-dose Pazopanib in Pediatric Cohort
DRUG: Spartalizumab in Adult cohort
DRUG: Low-dose Pazopanib in Adult Cohort

Sponsor

University Hospital, Bordeaux

Collaborators

[object Object]
[object Object]
[object Object]